Director Graydon Bensler Discloses 7.4% Stake in PMGC Holdings via Options for Consulting Services
ELAB is trading near its 52-week low of $1.62 (12% above the low) on light trading volume (0.1× avg).
Summary
Director Graydon Bensler and his entity, GB Capital Ltd., have reported a new 7.40% stake in PMGC Holdings, primarily through options received as compensation for consulting services.
Key Events · Ownership and Investor Activity · ELAB
-
New Significant Insider Stake
Director Graydon Bensler and GB Capital Ltd. disclosed a 7.40% beneficial ownership stake in PMGC Holdings Inc., totaling 450,287 shares.
-
Stake Acquired as Compensation
The majority of this stake (450,277 shares) was acquired through options granted on June 1, 2026, as partial consideration for consulting services provided by GB Capital Ltd.
-
Substantial Value for Micro-Cap
The reported stake is valued at approximately $815,000, representing nearly 10% of the company's current market capitalization.
-
Context of Financial Distress
This disclosure follows recent filings indicating a "going concern" warning and multiple dilutive equity financing events for PMGC Holdings.
Analysis · ELAB · Life Sciences
Director Graydon Bensler, through his wholly-owned entity GB Capital Ltd., has disclosed a new 7.40% beneficial ownership stake in PMGC Holdings Inc. This stake, valued at approximately $815,000, was primarily acquired through options granted as partial compensation for consulting services. This significant insider ownership aligns Mr. Bensler's interests with the company's performance, particularly as the company navigates a "going concern" warning and recent dilutive financing activities.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELAB was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $1.62 to $309.12. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.